News | June 05, 2021
Jubilant Pharmova posts Q4FY21 consolidated PAT of Rs. 213.90 Cr
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1140.01 crores during FY 2020-21
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Subscribe To Our Newsletter & Stay Updated
